Mayne Pharma Appoints Blake Cullen VP Business Development for U.S. Generics
He brings 15+ years of pharma industry experience in strategic planning, mergers and acquisitions, and product in-licensing and out-licensing.
Greenville, NC, June 16, 2014 --(PR.com)-- Mayne Pharma has appointed Blake Cullen as vice president of business development for its U.S. generic products division.
Cullen – who holds both a law degree and an MBA – will identify and pursue new business opportunities on behalf of Mayne Pharma’s generics products division, one of the fastest-growing U.S. generics businesses in recent years. The company’s generics business – established less than 10 years ago – currently markets more than 20 products and has 25 products under development with 13 ANDAs filed with the FDA.
Expansion of Mayne Pharma’s U.S. product portfolio will come through organic development and bolt-on acquisitions, said Stefan Cross, president of Mayne Pharma.
“In addition to his executive management experience, Blake brings to Mayne Pharma a strong track record of building pharmaceutical product lines and corporate value,” Cross said. “Blake’s deep understanding of the marketplace and his established relationships in the industry will serve Mayne Pharma well as we grow our U.S. business. I welcome Blake to our team.”
Cullen brings to Mayne Pharma 15-plus years of pharmaceutical industry experience in the areas of strategic planning, mergers and acquisitions, and product in-licensing and out-licensing. Prior to joining Mayne Pharma, he held business development roles with Rhodes Pharma, Libertas Pharma, Paddock Labs and Prasco Labs. He also served as general counsel at Qualitest Pharmaceuticals.
Cullen earned both his juris doctor degree and master of business administration degree from the University of Cincinnati. He received a bachelor of science degree from Seton Hall University.
About Mayne Pharma
Mayne Pharma is a publicly traded specialty pharmaceutical company listed on the Australian Securities Exchange (ASX: MYX). The company develops and manufactures branded and generic product globally – either directly or through distribution partners – while applying its drug-delivery expertise for contract development and manufacturing services.
Mayne Pharma has a 30-year track record of innovation and success in developing new oral drug delivery systems, and these technologies have been successfully commercialized in numerous products that have been marketed around the world.
Mayne Pharma has drug development and manufacturing facilities in Salisbury, Australia, with expertise in formulating complex oral dose forms, including controlled substances, modified release products and inherently unstable compounds.
About Mayne Pharma in the United States
Mayne Pharma’s operations in the United States consist of two main business segments that focus on contract pharmaceutical services and the development and manufacturing of branded and generic pharmaceutical products.
Through Mayne Pharma’s contract-services subsidiary, Metrics Inc., the company offers pharmaceutical development and manufacturing services to clients worldwide. Areas of expertise include pharmaceutical formulation development; first-time-in-man formulations; clinical trial materials manufacturing for Phase I, II, and III trials; and analytical method development and validation services leading to commercial-scale manufacturing.
Metrics’ capabilities include highly potent, cytotoxic and unstable compounds; Schedule II-V controlled substances; and products with poor bioequivalence, for which Mayne Pharma offers a vast portfolio of drug delivery methods.
Mayne Pharma also distributes a range of branded and generic pharmaceutical products through subsidiaries that include Midlothian Inc. and Libertas Pharma.
Cullen – who holds both a law degree and an MBA – will identify and pursue new business opportunities on behalf of Mayne Pharma’s generics products division, one of the fastest-growing U.S. generics businesses in recent years. The company’s generics business – established less than 10 years ago – currently markets more than 20 products and has 25 products under development with 13 ANDAs filed with the FDA.
Expansion of Mayne Pharma’s U.S. product portfolio will come through organic development and bolt-on acquisitions, said Stefan Cross, president of Mayne Pharma.
“In addition to his executive management experience, Blake brings to Mayne Pharma a strong track record of building pharmaceutical product lines and corporate value,” Cross said. “Blake’s deep understanding of the marketplace and his established relationships in the industry will serve Mayne Pharma well as we grow our U.S. business. I welcome Blake to our team.”
Cullen brings to Mayne Pharma 15-plus years of pharmaceutical industry experience in the areas of strategic planning, mergers and acquisitions, and product in-licensing and out-licensing. Prior to joining Mayne Pharma, he held business development roles with Rhodes Pharma, Libertas Pharma, Paddock Labs and Prasco Labs. He also served as general counsel at Qualitest Pharmaceuticals.
Cullen earned both his juris doctor degree and master of business administration degree from the University of Cincinnati. He received a bachelor of science degree from Seton Hall University.
About Mayne Pharma
Mayne Pharma is a publicly traded specialty pharmaceutical company listed on the Australian Securities Exchange (ASX: MYX). The company develops and manufactures branded and generic product globally – either directly or through distribution partners – while applying its drug-delivery expertise for contract development and manufacturing services.
Mayne Pharma has a 30-year track record of innovation and success in developing new oral drug delivery systems, and these technologies have been successfully commercialized in numerous products that have been marketed around the world.
Mayne Pharma has drug development and manufacturing facilities in Salisbury, Australia, with expertise in formulating complex oral dose forms, including controlled substances, modified release products and inherently unstable compounds.
About Mayne Pharma in the United States
Mayne Pharma’s operations in the United States consist of two main business segments that focus on contract pharmaceutical services and the development and manufacturing of branded and generic pharmaceutical products.
Through Mayne Pharma’s contract-services subsidiary, Metrics Inc., the company offers pharmaceutical development and manufacturing services to clients worldwide. Areas of expertise include pharmaceutical formulation development; first-time-in-man formulations; clinical trial materials manufacturing for Phase I, II, and III trials; and analytical method development and validation services leading to commercial-scale manufacturing.
Metrics’ capabilities include highly potent, cytotoxic and unstable compounds; Schedule II-V controlled substances; and products with poor bioequivalence, for which Mayne Pharma offers a vast portfolio of drug delivery methods.
Mayne Pharma also distributes a range of branded and generic pharmaceutical products through subsidiaries that include Midlothian Inc. and Libertas Pharma.
Contact
Mayne Pharma USA
Karen Stinneford
919.833.9102
www.maynepharma.com
Karen Stinneford
919.833.9102
www.maynepharma.com
Contact
Categories